Genetic disruption of either mouse or human proopiomelanocortin (POMC) causes earlyonset obesity (1-3), highlighting a major role of POMC in the regulation of energy homeostasis. POMC is processed posttranslationally into multiple peptides, including the opioid β-endorphin and the melanocortins ACTH, α-melanocyte stimulating hormone (αMSH), βMSH, and γMSH. POMC peptides in the CNS are essential in the regulation of energy intake and expenditure as demonstrated in studies using compound mutant mice (Pomc -/-Tg/+) expressing a Pomc transgene that selectively restored pituitary POMC in Pomc -/-mice to produce a neural-selective POMC-deficiency (4) . Lack of α-MSH is likely the principal cause of obesity (3, 5) due to the loss of agonist signaling at central melanocortin receptors (MC-R), MC3-R and MC4-R, each of which plays a distinct role in the regulation of energy homeostasis (6) (7) (8) .
The anorectic actions of centrally administered αMSH or the synthetic MC3/4-R agonist MTII (9) (10) (11) are blocked by Agouti Related Peptide (AgRP), an endogenous MC3/4-R antagonist (12, 13) , released from terminals of neuropeptide Y/AgRP arcuate neurons. In addition to their localization to the same brain regions as POMC fibers (14) , AgRP nerve terminals send projections to neurons that possess MC4-R (15) but are not innervated by αMSH terminals (14, 16) . These neuroanatomic findings indicate that AgRP may modulate MC4-R activity in the absence of endogenous αMSH.
In vitro data strongly support the ability of AgRP to modulate MC4-R by an inverse agonist mode of action (17) (18) (19) (20) , however the physiological significance is unresolved. Modulation of MC4-R constitutive activity may be important to maintain long-term energy homeostasis in humans (21) . In rodents, the concept of inverse agonism has been buttressed by demonstrations that a single injection of AgRP induces hyperphagia over several days (22) (23) (24) whereas this longlasting effect cannot be reproduced by synthetic MC4-R antagonists like HS014 or JKC-363 (23, 25) .
In the present study, we analyzed the feeding and metabolic responses to intracerebroventricular (icv) injections of MTII and AgRP in mice deficient in all central MSH peptides. Because responses to melanocortin antagonists apparently require the presence of circulating glucocorticoids (26) , we compared Pomc -/-mice with a global deficiency of POMC and adrenal insufficiency to Pomc -/-Tg/+ mice with a neural-specific deficiency of POMC but restored glucocorticoids (4) . Feeding effects of the orexigenic gut peptide ghrelin (27) were also tested.
RESEARCH DESIGN AND METHODS

Animals.
A colony of Pomc mutant mice on a hybrid B6;D2;129X1;129S6 genetic background with independently segregating Pomc +/-and pHalEx2* Tg alleles was established as described previously (4) . Mice were maintained under controlled temperature and photoperiod (12 h light, 12 h dark; lights on at 07:00) with free access to water and chow (4.5% fat, 20% protein, 6% fiber, 3.4 kcal/g; PicoLab Rodent Diet 20, PMI Nutrition International, St. Louis, MO). Experimental procedures were approved by the Institutional Animal Care and Use Committee and followed Public Health Service guidelines.
Peptides. MTII, hAgRP (83-132), mAgRP (82-131), and rGhrelin were purchased from Phoenix Pharmaceuticals (Mountain View, CA) and dissolved in physiological saline.
ICV cannulation.
Mice were anesthetized with 2% Avertin. 26-gauge stainless steel guide cannulae cut 2.5 mm below the pedestal (Plastics one, Roanoke, VA) were implanted stereotaxically into the right lateral ventricle (posterior -0.4 mm, lateral -1.0 mm, relative to bregma), secured to the skull using cap screws (Small Parts Inc.) and dental cement, and occluded with stainless steel dummy obturators. Mice were then housed individually for 7-10 days of recovery without specific treatment, except the Pomc -/-mice that required injection with dexamethasone (0.15 µg ip in 1 ml saline) for 3 days.
Feeding and basal metabolic rate. Peptides were injected icv in a volume of 1 µl over 1 min using a 33-gauge stainless steel injection cannula extending 0.5 mm below the guide cannula and connected to a 1 µl Hamilton syringe with polyethylene tubing. Mice were returned to their home cage and the remaining food in containers on the cage floor was weighed at different time intervals. Basal metabolic rate was determined by indirect open-circuit calorimetry (Oxymax, Columbus Instruments) as previously described (4). After three days of chamber habituation, six measurements were recorded daily from each mouse at 60 min intervals. Individual basal oxygen consumption (VO 2 ) levels were established by averaging the two lowest VO 2 measurements. Respiratory exchange ratios (RER) were recorded as the molar ratio of VCO 2 to VO 2 and a daily average value was calculated.
Experimental Design. Male and female mice were used in all experiments. Peptides or saline were administered between 11:00 am and 12:00 pm for day-time experiments and between 6:00 and 7:00 pm (lights-off at 7:00 pm) for night-time experiments. Mice were randomized into different groups based on their 24 h food intake before experiments and received each dose of peptide and saline in a Figure 1A) . In Pomc +/+ Tg/+ mice, food intake was inhibited 67% and the effect was completely reversed by 24h ( Figure 1A and B Figure 1C ).
Feeding effects of co-administered MTII and AgRP.
To test the ability of AgRP to antagonize MSH agonists at MC3/4-R, 0.5 nmol AgRP was injected alone or in combination with 0.1 nmol MTII at the onset of the dark cycle. Although this lower dose of MTII was slightly less potent than 0.5 nmol to reduce feeding 2h after injection, we chose it in combination with AgRP because its anorectic effects had dissipated in all genotypes at 24h. There was a significant main effect of the peptide treatments on 2h food intake but no significant interaction of treatment x genotype ( Figure 2A ). Post-hoc analyses collapsed across genotype confirmed that 0.1 nmol MTII alone significantly decreased acute food intake (P<0.0001 vs. saline). In contrast, there was no significant main effect of treatment or treatment x genotype interaction on 24h food intake ( Figure 2B ). After night-time injection, when maximum feeding activity is already observed, there was no additive, short-term orexigenic effect of 0.5 nmol AgRP alone on any genotype. However, AgRP significantly blocked the anorectic effect of 0.1 nmol MTII in all genotypes 2h after co-injection of both peptides (P<0.0001, AgRP+MTII vs MTII alone, Fisher PLSD) (Figure 2A ), consistent with a competitive antagonist action at the MC3/4-R. Analyses performed for the relevant, genotype-specific time-frames showed an increased body weight of 12% over 3d in Pomc +/+ Tg/+ (P<0.01) and 6% over 6d in Pomc -/-Tg/+ (P<0.01) mice after AgRP treatment, compared to their initial body weights. In Pomc +/+ Tg/+ mice, increased daily food consumption, increased average daily RER and decreased VO 2 were observed within 24h following the injection (0-24h) and were sustained up to 72h after the injection (24-72h) ( Figure 5C , E and G). In contrast, none of the parameters were modified within 24h following AgRP injection (0-24h) in Pomc -/-Tg/+ mice, but the delayed effects on food intake, VO 2 and RER were significant between 24-72h and persisted up to 168h ( Figure 5D, F and H) . In vitro studies have clearly demonstrated that AgRP acts as both a competitive antagonist and an inverse agonist at MC4R and MC3-R to modulate cAMP levels (17) (18) (19) (20) 37) . Furthermore, in a recent study, AgRP was shown to exhibit agonistic properties on both MC3-R and MC4-R expressed in HEK293 cells by inducing arrestin-mediated endocytosis (38) (39) . Here, we show that CART, another factor involved in the control of the HPA axis and possessing anorectic effects (40) , is also up-regulated in POMC-deficient mice. Therefore, elevated CRH and CART tone may counterbalance the feeding effects of AgRP and explain its apparently subtle orexigenic action in Pomc -/-Tg/+ mice. Pomc -/-mice that did not receive glucocorticoid replacement exhibited the most profound catabolic responses to icv injections of saline, but also to AgRP. These latter results support previous studies showing that AgRP's actions on energy balance in adrenalectomized rats are glucocorticoid-dependent (26) . Severe dysregulation of their HPA axis due to adrenal insufficiency (39, 41, 42) and upregulated CRH expression in the PVH likely explain the paradoxical anorectic response of Pomc -/-mice.
Short-term feeding effects of
Independently of the modulation of food intake, AgRP also modulates energy expenditure (43, 44) . We therefore performed indirect calorimetry to determine if the weight gain in Pomc -/-Tg/+ mice could be partly due to decreased VO 2 and/or modification in energy substrate utilization. Under specific experimental conditions where access to food was limited to 16h each day, a significant but discrete increase in food consumption together with decreased basal metabolic rate and increased average RER were measured in the mice. Compared to Pomc +/+ Tg/+ mice, the AgRP responses observed in Pomc -/-Tg/+ mice were of smaller amplitude but longer duration with delayed onset, supporting a distinct mechanism of action of AgRP based on the genotype, which may reflect the lack of short-term antagonist action at MC3/4-R.
Specific brain targets of these metabolic actions of AgRP in Pomc -/-
Tg/+ mice remain to be determined. The central melanocortin system regulates the activities of both the sympathetic nervous system and the hypothalamic-pituitary-thyroid axis, which act in synergy to control thermogenesis (45) . The presence of AgRP but not αMSH terminals on some TRH neurons expressing MC4-R suggests that these neurons are good candidates (16) . Using MC4-R deficient mice, several laboratories have independently demonstrated a critical role for MC4-R in maintaining basal metabolic activity (46, 47) . However, short-term and long-term hyperphagic actions of AgRP were still observed in MC4-R KO mice, suggesting that MC4-R is not the only receptor to mediate effects of the orexigenic peptide. Interestingly, MC3-R regulates partitioning of fuel stores into fat rather than directly affecting food consumption (6, 7). In our study, the increased RER after AgRP treatment suggests a switch from carbohydrate to fat stores as a source of energy and this may be mediated through a MC3-R mechanism of action. As the hypothalamic expression of MC4-R and MC3-R was unchanged in the mutant mice, we cannot distinguish between the possible involvement of either receptor to induce AgRP's effects.
In conclusion, neuronal-specific POMCdeficient mice that lack αMSH signaling in the CNS have increased sensitivity to melanocortin agonists and respond with altered kinetics to the feeding and metabolic actions of AgRP. These data demonstrate that exogenous AgRP can modulate energy balance in the CNS independently of MC3/4-R competitive antagonism and strongly support an inverse agonist mode of action for AgRP in vivo. However, it is a possibility that long-lasting AgRP actions in Pomc -/-Tg/+ mice may be relayed by a mechanism involving receptors distinct from MC3 and MC4-R. To further test the contribution of each proposed AgRP mode of action, utilization of additional pharmacological tools is necessary. If endogenous AgRP actually functions as an inverse agonist at either MC-R, a pure selective competitive MC-R antagonist should block endogenous AgRP action and decrease food intake and/or body weight in POMC-deficient mice, while having the opposite effect in wild-type mice. Current obstacles to perform or interpret the results of such experiments depend on the availability of selective compounds and the possibility that synthetic antagonists may also behave as inverse agonists. Alternatively, utilization of siRNA technology to block endogenous AgRP in POMC-deficient mice or breeding of AgRP KO to neural-specific POMC-deficient mice to create double AgRP/nPOMC KO mice would be useful approaches to better understand the mechanism of action of the endogenous orexigenic peptide.
The physiological significance of the putative inverse agonist action in humans still remains to be determined. A recent study in obese patients that identified mutations in the extracellular N terminal domain of MC4-R associated with loss of constitutive activity suggests that modulation of constitutive activity in wild-type receptors by inverse agonists could be important to maintain longterm energy homeostasis in humans (21) . Supporting this possibility are recent reports that the human MC4-R undergoes ligandindependent cycles of endo-and exocytosis in transfected neuroblastoma cells and immortalized hypothalamic neurons (48) and antibodies directed against an epitope in the N terminal domain of the MC4-R act as inverse agonists in cell lines and intact animal models (49) . Assessment of the effects of AgRP in knock-in mouse models containing humanized MC4-R with the inactivating N terminal mutations, or other characterized, constitutively active receptors that respond solely to a synthetic ligand (RASSLs) (50) would be useful to confirm that AgRP's mechanism of action is partly mediated through modulation of MC4-R constitutive activity. Tg/+ mice (6 days). All other data are mean±SEM, n=7-8 (C-F). Paired T-tests showed a significant effect of AgRP on food intake, VO2 and RER. *P<0.05, **P<0.01, ***P<0.001 vs saline. 
